Prostaglandin E2 potentiates mesenchymal stem cell-induced IL-10+IFN-γ+CD4+ regulatory T cells to control transplant arteriosclerosis

Journal of Immunology

Volumn 190, Issue 5, 2013, Pages 2372-2380

  Hsu, Wan Tseng ^a,b   Lin, Cheng Hsin ^a   Chiang, Bor Luen ^a   Jui, Hsiang Yiang ^a,c   Wu, Kenneth Kun Yu ^b   Lee, Chii Ming ^a,b,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; MISOPROSTOL; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTERIOSCLEROSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL THERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; HOST RESISTANCE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; MIXED LYMPHOCYTE REACTION; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REGULATORY T LYMPHOCYTE; SWINE; UPREGULATION; ALLOTRANSPLANTATION; ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECT; FEMORAL ARTERY; GENE EXPRESSION; IMMUNOLOGY; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; SECRETION (PROCESS); TRANSPLANTATION;

ANIMALS; ARTERIOSCLEROSIS; CELL PROLIFERATION; DINOPROSTONE; FEMORAL ARTERY; GENE EXPRESSION; IMMUNE TOLERANCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; INTERLEUKIN-10; MESENCHYMAL STROMAL CELLS; SWINE; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS;

MLCS; MLOWN;

EID: 84874239821     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202996     Document Type: Article

References (49)

1. Isobe, M., H. Kosuge, and J. Suzuki. 2006. T cell costimulation in the development of cardiac allograft vasculopathy: potential targets for therapeutic interventions. Arterioscler. Thromb. Vasc. Biol. 26: 1447-1456.
2. Russell, P. S., C. M. Chase, H. J. Winn, and R. B. Colvin. 1994. Coronary atherosclerosis in transplanted mouse hearts. I. Time course and immunogenetic and immunopathological considerations. Am. J. Pathol. 144: 260-274.
3. Zappia, E., S. Casazza, E. Pedemonte, F. Benvenuto, I. Bonanni, E. Gerdoni, D. Giunti, A. Ceravolo, F. Cazzanti, F. Frassoni, et al. 2005. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106: 1755-1761.
4. Chang, J. W., S. P. Hung, H. H. Wu, W. M. Wu, A. H. Yang, H. L. Tsai, L. Y. Yang, and O. K. Lee. 2011. Therapeutic effects of umbilical cord bloodderived mesenchymal stem cell transplantation in experimental lupus nephritis. Cell Transplant. 20: 245-257.
5. Nemeth, K., A. Keane-Myers, J. M. Brown, D. D. Metcalfe, J. D. Gorham, V. G. Bundoc, M. G. Hodges, I. Jelinek, S. Madala, S. Karpati, and E. Mezey. 2010. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. [Published erratum appears in 2010 Proc. Natl. Acad. Sci. USA 107: 8041.] Proc. Natl. Acad. Sci. USA 107: 5652-5657.
6. Bartholomew, A., C. Sturgeon, M. Siatskas, K. Ferrer, K. McIntosh, S. Patil, W. Hardy, S. Devine, D. Ucker, R. Deans, et al. 2002. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30: 42-48.
7. Casiraghi, F., N. Azzollini, P. Cassis, B. Imberti, M. Morigi, D. Cugini, R. A. Cavinato, M. Todeschini, S. Solini, A. Sonzogni, et al. 2008. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J. Immunol. 181: 3933-3946.
8. Ge, W., J. Jiang, J. Arp, W. Liu, B. Garcia, and H. Wang. 2010. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation 90: 1312-1320.
9. Djouad, F., P. Plence, C. Bony, P. Tropel, F. Apparailly, J. Sany, D. Noël, and C. Jorgensen. 2003. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102: 3837-3844.
10. Aggarwal, S., and M. F. Pittenger. 2005. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105: 1815-1822.
11. Maccario, R., M. Podestà, A. Moretta, A. Cometa, P. Comoli, D. Montagna, L. Daudt, A. Ibatici, G. Piaggio, S. Pozzi, et al. 2005. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/ suppressive phenotype. Haematologica 90: 516-525.
12. Prevosto, C., M. Zancolli, P. Canevali, M. R. Zocchi, and A. Poggi. 2007. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem celllymphocyte interaction. Haematologica 92: 881-888.
13. Di Ianni, M., B. Del Papa, M. De Ioanni, L. Moretti, E. Bonifacio, D. Cecchini, P. Sportoletti, F. Falzetti, and A. Tabilio. 2008. Mesenchymal cells recruit and regulate T regulatory cells. Exp. Hematol. 36: 309-318.
14. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061.
15. Groux, H., A. O'Garra, M. Bigler, M. Rouleau, S. Antonenko, J. E. de Vries, and M. G. Roncarolo. 1997. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389: 737-742.
16. Vieira, P. L., J. R. Christensen, S. Minaee, E. J. O'Neill, F. J. Barrat, A. Boonstra, T. Barthlott, B. Stockinger, D. C. Wraith, and A. O'Garra. 2004. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J. Immunol. 172: 5986-5993.
17. Levings, M. K., R. Sangregorio, F. Galbiati, S. Squadrone, R. de Waal Malefyt, and M. G. Roncarolo. 2001. IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J. Immunol. 166: 5530-5539.
18. Kemper, C., A. C. Chan, J. M. Green, K. A. Brett, K. M. Murphy, and J. P. Atkinson. 2003. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 421: 388-392.
19. Awasthi, A., Y. Carrier, J. P. Peron, E. Bettelli, M. Kamanaka, R. A. Flavell, V. K. Kuchroo, M. Oukka, and H. L. Weiner. 2007. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat. Immunol. 8: 1380-1389.
20. Meiffren, G., M. Flacher, O. Azocar, C. Rabourdin-Combe, and M. Faure. 2006. Cutting edge: abortive proliferation of CD46-induced Tr1-like cells due to a defective Akt/Survivin signaling pathway. J. Immunol. 177: 4957-4961.
21. Häringer, B., L. Lozza, B. Steckel, and J. Geginat. 2009. Identification and characterization of IL-10/IFN-gamma-producing effector-like T cells with regulatory function in human blood. J. Exp. Med. 206: 1009-1017.
22. Zhou, Y., H. Kawasaki, S. C. Hsu, R. T. Lee, X. Yao, B. Plunkett, J. Fu, K. Yang, Y. C. Lee, and S. K. Huang. 2010. Oral tolerance to food-induced systemic anaphylaxis mediated by the C-type lectin SIGNR1. Nat. Med. 16: 1128-1133.
23. Wang, H., R. Meng, Z. Li, B. Yang, Y. Liu, F. Huang, J. Zhang, H. Chen, and C. Wu. 2011. IL-27 induces the differentiation of Tr1-like cells from human naive CD4+ T cells via the phosphorylation of STAT1 and STAT3. Immunol. Lett. 136: 21-28.
24. Mougiakakos, D., R. Jitschin, C. C. Johansson, R. Okita, R. Kiessling, and K. Le Blanc. 2011. The impact of inflammatory licensing on heme oxygenase-1- mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 117: 4826-4835.
25. English, K., J. M. Ryan, L. Tobin, M. J. Murphy, F. P. Barry, and B. P. Mahon. 2009. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4 +CD25(High) forkhead box P3+ regulatory T cells. Clin. Exp. Immunol. 156: 149-160.
26. Najar, M., G. Raicevic, H. I. Boufker, H. Fayyad Kazan, C. De Bruyn, N. Meuleman, D. Bron, M. Toungouz, and L. Lagneaux. 2010. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell. Immunol. 264: 171-179.
27. Chen, K., D. Wang, W. T. Du, Z. B. Han, H. Ren, Y. Chi, S. G. Yang, D. Zhu, F. Bayard, and Z. C. Han. 2010. Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism. Clin. Immunol. 135: 448-458.
28. Krampera, M., L. Cosmi, R. Angeli, A. Pasini, F. Liotta, A. Andreini, V. Santarlasci, B. Mazzinghi, G. Pizzolo, F. Vinante, et al. 2006. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24: 386-398.
29. English, K., F. P. Barry, C. P. Field-Corbett, and B. P. Mahon. 2007. IFN-gamma and TNF-αlpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol. Lett. 110: 91-100.
30. Deuse, T., M. Stubbendorff, K. Tang-Quan, N. Phillips, M. A. Kay, T. Eiermann, T. T. Phan, H. D. Volk, H. Reichenspurner, R. C. Robbins, and S. Schrepfer. 2011. Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant. 20: 655-667.
31. Stone, T. W., and L. G. Darlington. 2002. Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discov. 1: 609-620.
32. Akasaki, Y., G. Liu, N. H. Chung, M. Ehtesham, K. L. Black, and J. S. Yu. 2004. Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2- overexpressing glioma. J. Immunol. 173: 4352-4359.
33. Bergmann, C., L. Strauss, R. Zeidler, S. Lang, and T. L. Whiteside. 2007. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res. 67: 8865-8873.
34. Kavousanaki, M., A. Makrigiannakis, D. Boumpas, and P. Verginis. 2010. Novel role of plasmacytoid dendritic cells in humans: induction of interleukin-10- producing Treg cells by plasmacytoid dendritic cells in patients with rheumatoid arthritis responding to therapy. Arthritis Rheum. 62: 53-63.
35. Jui, H. Y., C. H. Lin, W. T. Hsu, Y. R. Liu, R. B. Hsu, B. L. Chiang, W. Y. Tseng, M. F. Chen, K. K. Wu, and C. M. Lee. 2012. Autologous mesenchymal stem cells prevent transplant arteriosclerosis by enhancing local expression of interleukin-10, interferon-g, and indoleamine 2,3-dioxygenase. Cell Transplant. 21: 971-984.
36. von Bergwelt-Baildon, M. S., A. Popov, T. Saric, J. Chemnitz, S. Classen, M. S. Stoffel, F. Fiore, U. Roth, M. Beyer, S. Debey, et al. 2006. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 108: 228-237.
37. Lanzinger, M., B. Jü rgens, U. Hainz, B. Dillinger, J. Raberger, D. Fuchs, and A. Heitger. 2012. Ambivalent effects of dendritic cells displaying prostaglandin E2-induced indoleamine 2,3-dioxygenase. Eur. J. Immunol. 42: 1117-1128.
38. Thebault, P., T. Condamine, M. Heslan, M. Hill, I. Bernard, A. Saoudi, R. Josien, I. Anegon, M. C. Cuturi, and E. Chiffoleau. 2007. Role of IFNgamma in allograft tolerance mediated by CD4+CD25+ regulatory T cells by induction of IDO in endothelial cells. Am. J. Transplant. 7: 2472-2482.
39. Yanagawa, Y., K. Iwabuchi, and K. Onoé. 2009. Co-operative action of interleukin-10 and interferon-gamma to regulate dendritic cell functions. Immunology 127: 345-353.
40. Braun, D., R. S. Longman, and M. L. Albert. 2005. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 106: 2375-2381.
41. Basu, G. D., T. L. Tinder, J. M. Bradley, T. Tu, C. L. Hattrup, B. A. Pockaj, and P. Mukherjee. 2006. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J. Immunol. 177: 2391-2402.
42. Jung, I. D., Y. I. Jeong, C. M. Lee, K. T. Noh, S. K. Jeong, S. H. Chun, O. H. Choi, W. S. Park, J. Han, Y. K. Shin, et al. 2010. COX-2 and PGE2 signaling is essential for the regulation of IDO expression by curcumin in murine bone marrow-derived dendritic cells. Int. Immunopharmacol. 10: 760-768.
43. Abramovitz, M., M. Adam, Y. Boie, M. Carrière, D. Denis, C. Godbout, S. Lamontagne, C. Rochette, N. Sawyer, N. M. Tremblay, et al. 2000. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim. Biophys. Acta 1483: 285-293.
44. Haynes, D. R., M. W. Whitehouse, and B. Vernon-Roberts. 1992. The prostaglandin E1 analogue, misoprostol, regulates inflammatory cytokines and immune functions in vitro like the natural prostaglandins E1, E2 and E3. Immunology 76: 251-257.
45. Van Elssen, C. H., J. Vanderlocht, T. Oth, B. L. Senden-Gijsbers, W. T. Germeraad, and G. M. Bos. 2011. Inflammation-restraining effects of prostaglandin E2 on natural killer-dendritic cell (NK-DC) interaction are imprinted during DC maturation. Blood 118: 2473-2482.
46. Moran, M., M. F. Mozes, M. S. Maddux, S. Veremis, C. Bartkus, B. Ketel, R. Pollak, C. Wallemark, and O. Jonasson. 1990. Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone. N. Engl. J. Med. 322: 1183-1188.
47. Kalinski, P. 2012. Regulation of immune responses by prostaglandin E2. J. Immunol. 188: 21-28.
48. Battaglia, M., A. Stabilini, E. Draghici, B. Migliavacca, S. Gregori, E. Bonifacio, and M. G. Roncarolo. 2006. Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory cells and T regulatory type 1 cells. Diabetes 55: 1571-1580.
49. Cheon, H., Y. H. Rho, S. J. Choi, Y. H. Lee, G. G. Song, J. Sohn, N. H. Won, and J. D. Ji. 2006. Prostaglandin E2 augments IL-10 signaling and function. J. Immunol. 177: 1092-1100.